CITIUS ONCOLOGY, INC.

Citius Oncology, Inc., trading under the ticker TENK, is the oncology-focused biopharmaceutical company formed through the business combination of TenX Keane Acquisition Corp and the oncology assets spun off from Citius Pharmaceuticals. TenX Keane Acquisition Corp, sponsored by TenX Keane Holdings LLC, completed its initial public offering in 2021 with a mandate targeting the healthcare and life sciences sector. The 8-K filed on August 5, 2024 relates to post-combination corporate disclosures as Citius Oncology establishes itself as a standalone public company in the oncology therapeutics space. For complete filing timelines, sponsor data, and deal analytics on TENK and the broader SPAC universe, sign up for full access at SpacDesk.